Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.

Luca MastorinoP DapavoLorenza BurziF RossetI Giunipero di CorteranzoF LeoA VerroneE StroppianaM OrtoncelliSimone Ribero Pietro Quaglino

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Ixekizumab showed high effectiveness and safety for up to 5 years, with survival of 2/3 of treated patients. Rapid response to treatment is predictive of long-term response.

Keyphrases

free survival
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
emergency department
drug induced
adverse drug
electronic health record